Literature DB >> 8491498

Properties of the random zero sphygmomanometer.

R A Kronmal1, G H Rutan, T A Manolio, N O Borhani.   

Abstract

The random zero sphygmomanometer is widely used in studies involving blood pressure measurement because it is believed to eliminate digit preference and reduce measurement error. We performed blood pressure measurements sequentially using random zero and standard sphygmomanometers in random order in 1,356 participants in the Cardiovascular Health Study. Despite adherence to the manufacturer's instructions, we observed a substantially nonuniform distribution of zero levels generated by the random zero sphygmomanometer and a disturbing correlation between the zero level and blood pressures taken with the standard sphygmomanometer. With the random zero device, the pooled estimated slopes for the regression of standard systolic and diastolic pressures on the zero level were -0.71 and -0.17, respectively (both p < 0.0001). The only plausible explanation for this relation between the random zero device and the standard device is that by some unknown mechanism the subject's blood pressure is influencing the zero level. Systolic and diastolic blood pressures measured with the random zero device were, respectively, 1.65 and 1.84 mm Hg lower (both p < 0.0001) than standard blood pressures. Digit preference was detectable in the uncorrected blood pressure and zero level measured with the random zero device but was eliminated after calculation of the corrected blood pressure. For most epidemiological studies, the random zero sphygmomanometer offers no significant advantage over the standard sphygmomanometer. It may still be useful in those epidemiological studies and clinical trials where blinding is important.

Entities:  

Mesh:

Year:  1993        PMID: 8491498     DOI: 10.1161/01.hyp.21.5.632

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  The Hawksley random zero sphygmomanometer. Comparison with mercury instrument is illogical.

Authors:  H W Hense
Journal:  BMJ       Date:  1993-08-28

2.  Calibration of blood pressure measurements in the Jackson Heart Study.

Authors:  Samantha R Seals; Lisandro D Colantonio; Jonathan V Tingle; Daichi Shimbo; Adolfo Correa; Michael E Griswold; Paul Muntner
Journal:  Blood Press Monit       Date:  2019-06       Impact factor: 1.444

3.  Randomized controlled trial of stress reduction with meditation and health education in black men and women with high normal and normal blood pressure.

Authors:  Robert H Schneider; Clarence Grim; Theodore Kotchen; Komal Marwaha; Jane Kotchen; John W Salerno; Carolyn Gaylord King; Sanford Nidich; Charles N Alexander
Journal:  Am J Prev Cardiol       Date:  2021-10-04

4.  Humoral and haemodynamic effects of idrapril calcium, the prototype of a new class of ACE-inhibitors, in essential hypertensive patients.

Authors:  S Taddei; L Ghiadoni; P Mattei; I Sudano; P Duranti; S Favilla; A Virdis; A Romagnoli; M Criscuoli; A Coppini
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Agreement of blood pressure measurements between random-zero and standard mercury sphygmomanometers.

Authors:  Wenjie Yang; Dongfeng Gu; Jing Chen; Cashell E Jaquish; D C Rao; Xigui Wu; James E Hixson; Xiufang Duan; Tanika N Kelly; L Lee Hamm; Paul K Whelton; Jiang He
Journal:  Am J Med Sci       Date:  2008-11       Impact factor: 2.378

6.  Influence of change in aerobic fitness and weight on prevalence of metabolic syndrome.

Authors:  Laura A Crist; Catherine M Champagne; Leonor Corsino; Lillian F Lien; Guangyu Zhang; Deborah Rohm Young
Journal:  Prev Chronic Dis       Date:  2012-03-08       Impact factor: 2.830

7.  Conventional and Ambulatory Blood Pressure as Predictors of Retinal Arteriolar Narrowing.

Authors:  Fang-Fei Wei; Zhen-Yu Zhang; Lutgarde Thijs; Wen-Yi Yang; Lotte Jacobs; Nicholas Cauwenberghs; Yu-Mei Gu; Tatiana Kuznetsova; Karel Allegaert; Peter Verhamme; Yan Li; Harry A J Struijker-Boudier; Jan A Staessen
Journal:  Hypertension       Date:  2016-06-20       Impact factor: 10.190

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.